Form 4: Stoke Therapeutics Director Cancels Equity Awards

Stoke Therapeutics Director Edward M. Kaye canceled 178,500 stock options and 144,000 Restricted Stock Units by mutual agreement with the company.

Summary

• Edward M. Kaye, a Director of Stoke Therapeutics, Inc. (STOK), reported changes in his beneficial ownership on September 4, 2025.
• He disposed of 178,500 employee stock options with an exercise price of $8.33 per share. These options were partially canceled for no consideration by mutual agreement with the Issuer.
• Following this transaction, he beneficially owns 37,500 employee stock options.
• He also disposed of 144,000 Restricted Stock Units (RSUs). The entire RSU award was canceled for no consideration by mutual agreement with the Issuer.
• Following this transaction, he beneficially owns 0 Restricted Stock Units.
• The disposition of equity securities is exempt pursuant to Rule 16b-3(e) and 16b-6(d).

Sentiment

Score: 5

Explanation: The filing reports a director's disposition of a significant number of equity awards (stock options and RSUs) for no consideration by mutual agreement. While this reduces potential future dilution and compensation expense for the company, the underlying reasons for this action are not disclosed within the filing. The net effect on investor sentiment is ambiguous without additional context.

Positives

• The cancellation of 178,500 stock options and 144,000 Restricted Stock Units for no consideration reduces potential future dilution for existing shareholders.
• The company does not incur any cost for these canceled equity awards, potentially reducing future compensation expenses.

Negatives

• The director's overall beneficial ownership of derivative securities has significantly decreased, which could be interpreted as a reduction in direct equity incentive.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transaction involves the disposition of equity awards by a director (Edward M. Kaye) to the Issuer (Stoke Therapeutics, Inc.) by mutual agreement and for no consideration.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced future dilution and compensation expense due to the cancellation of equity awards for no consideration. Potential for neutral to slightly negative perception if the reduction in a director's equity holdings is interpreted as a lack of confidence, absent further explanation.

Key Dates

Recommendation

This Form 4 reports a factual transaction where a director canceled a substantial portion of their equity awards for no consideration. While this action reduces potential future dilution, the absence of a stated rationale for this mutual agreement makes it difficult to fully assess the implications for the company's future prospects or insider confidence. Investors should maintain their current position and await further information or clarification from the company.

Keywords

Stoke Therapeutics, STOK, Edward M. Kaye, Director, Stock Options, Restricted Stock Units, Equity Awards, Insider Transaction, Form 4, Beneficial Ownership